Brief: Abbisko Cayman Says Abbisko Therapeutics' CSF-1R Inhibitor Pimicotinib Approved By China NMPA
22/12/2025 10:29
Dec 22 (Reuters) - Abbisko Cayman Ltd 2256.HK: ABBISKO THERAPEUTICS' CSF-1R INHIBITOR PIMICOTINIB APPROVED BY THE CHINA NMPA Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly